Renaissance Technologies LLC reduced its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 26.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 137,500 shares of the company's stock after selling 49,937 shares during the period. Renaissance Technologies LLC owned 0.20% of EyePoint Pharmaceuticals worth $1,024,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in EyePoint Pharmaceuticals during the fourth quarter worth $59,000. AlphaQuest LLC grew its holdings in EyePoint Pharmaceuticals by 13,246.6% during the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after acquiring an additional 9,670 shares during the period. Raymond James Financial Inc. bought a new position in shares of EyePoint Pharmaceuticals in the 4th quarter worth about $76,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of EyePoint Pharmaceuticals by 40.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock valued at $108,000 after purchasing an additional 4,179 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in shares of EyePoint Pharmaceuticals by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company's stock valued at $113,000 after purchasing an additional 2,782 shares in the last quarter. 99.41% of the stock is owned by institutional investors.
EyePoint Pharmaceuticals Price Performance
Shares of NASDAQ:EYPT traded up $0.17 during midday trading on Friday, hitting $7.30. 690,968 shares of the company's stock were exchanged, compared to its average volume of 879,755. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $21.26. The company has a market cap of $502.32 million, a PE ratio of -3.65 and a beta of 1.39. The stock has a 50 day moving average price of $6.00 and a 200-day moving average price of $7.66.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million for the quarter, compared to analysts' expectations of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. On average, analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.
Analyst Ratings Changes
EYPT has been the subject of a number of research analyst reports. Chardan Capital reiterated a "buy" rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $26.63.
View Our Latest Research Report on EYPT
EyePoint Pharmaceuticals Company Profile
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
